Given that AAV has been used as a delivery vehicle in the COVID-19 vaccine, the local delivery of exogenous KCNN1 via AAV into the DRGs may hold potential as a novel antinociceptive treatment for managing neuropathic pain. Here, KCNN1 is linked to COVID-19.